Enlivex Therapeutics Ltd (NASDAQ: ENLV)’s stock price has gone rise by 15.14 in comparison to its previous close of 0.93, however, the company has experienced a 1.90% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra™ following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient.
Is It Worth Investing in Enlivex Therapeutics Ltd (NASDAQ: ENLV) Right Now?
Company’s 36-month beta value is 0.99.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENLV is 18.76M, and currently, short sellers hold a 0.85% ratio of that floaft. The average trading volume of ENLV on November 26, 2024 was 142.27K shares.
ENLV’s Market Performance
The stock of Enlivex Therapeutics Ltd (ENLV) has seen a 1.90% increase in the past week, with a -27.21% drop in the past month, and a -14.40% fall in the past quarter. The volatility ratio for the week is 15.66%, and the volatility levels for the past 30 days are at 10.47% for ENLV. The simple moving average for the past 20 days is -8.92% for ENLV’s stock, with a -42.04% simple moving average for the past 200 days.
Analysts’ Opinion of ENLV
Many brokerage firms have already submitted their reports for ENLV stocks, with H.C. Wainwright repeating the rating for ENLV by listing it as a “Buy.” The predicted price for ENLV in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on March 02, 2021 of the previous year 2021.
ENLV Trading at -23.03% from the 50-Day Moving Average
After a stumble in the market that brought ENLV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.69% of loss for the given period.
Volatility was left at 10.47%, however, over the last 30 days, the volatility rate increased by 15.66%, as shares sank -27.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.52% lower at present.
During the last 5 trading sessions, ENLV rose by +1.90%, which changed the moving average for the period of 200-days by -61.79% in comparison to the 20-day moving average, which settled at $1.1748. In addition, Enlivex Therapeutics Ltd saw -60.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENLV
The total capital return value is set at -0.64. Equity return is now at value -61.17, with -52.50 for asset returns.
Currently, EBITDA for the company is -28.22 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.06.
Conclusion
In a nutshell, Enlivex Therapeutics Ltd (ENLV) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
